Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/03/13 → 31/05/14 |
A phase III randomised double blind placebo controlled study of Vemurafenib (ro5185426) adjuvant therapy in patients with surgically resected, cutaneous braf mutant melanoma at high risk of recurrenc
- Parente, Phillip (Primary Chief Investigator (PCI))
Project: Research